Multiple myeloma: An update

Oman Medical Journal

Volumn 28, Issue 1, 2013, Pages 3-11

  Al Farsi, Khalil ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

Monoclonal gammopathy; Multiple myeloma; Myeloma; Plasma cell dyscrasia; Plasma cell myeloma

Indexed keywords

ACETYLSALICYLIC ACID; BENCE JONES PROTEIN; BORTEZOMIB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GADOLINIUM; INTERLEUKIN 6; LENALIDOMIDE; M PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THALIDOMIDE; VINCRISTINE;

AMYLOIDOSIS; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOPHENOTYPING; KIDNEY FAILURE; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 84873282340     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: 10.5001/omj.2013.02     Document Type: Review

References (72)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008 Mar;111(6):2962-2972.
2. Kyle RA, Terneau TM, Rajkumar SV, Larson DR, Plevak MF, Oford JR, et al. Prevalence of monoclonal gammopathy of undetermined signifcance. N Engl J Med 2006 Mar;354(13):1362-1369.
3. Kyle RA, Terneau TM, Rajkumar SV, Oford JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined signifcance. N Engl J Med 2002 Feb;346(8):564-569.
4. Kyle RA, Remstein ED, Terneau TM, Dispenzieri A, Kurtin PJ, Hodnefeld JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007 Jun;356(25):2582-2590.
5. Ministry of Health. Oman. Cancer Incidence in Oman: Report of 2009. Department of No n-Communicable Disease Surveillance and Control; Directorate General of Health Afairs, 2009.
6. Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, et al. Familial myeloma. N Engl J Med 2008 Jul;359(2):152-157.
7. Landgren O, Kyle RA, Pfeifer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined signifcance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009 May;113(22):5412-5417.
8. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al; International Myeloma Working Group. International Myeloma Working Group molecular classifcation of multiple myeloma: spotlight review. Leukemia 2009 Dec;23(12):2210-2221.
9. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011 Oct;29(28):3805-3812.
10. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 Jan;78(1):21-33.
11. Al-Farsi K, Al-Haddabi I, Al-Riyami N, Al-Sukaiti R, Al-Kindi S. Myelomatous Pleural Efusion: Case report and review of the literature. Sultan Qaboos Univ Med J 2011 May;11(2):259-264.
12. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009 Feb;23(2):215-224.
13. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia 2009 Sep;23(9):1545-1556.
14. International Myeloma Working Group. Criteria for the classifcation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003 Jun;121(5):749-757.
15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005 May;23(15):3412-3420.
16. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975 Sep;36(3):842-854.
17. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011 Jun;117(23):6063-6073.
18. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009 Oct;23(10):1716-1730.
19. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003 Jun;348(26):2609-2617.
20. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004 Oct;127(2):165-172.
21. Richardson PG, Sonneveld P, Schuster M W, Irwin D, Stadtmauer EA, Facon T, et al; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 Jun;352(24):2487-2498.
22. Kumar SK, Rajkumar S V, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008 Mar;111(5):2516-2520.
23. Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006 Jan;24(3):431-436.
24. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008 May;26(13):2171-2177.
25. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010 Oct;28(30):4621-4629.
26. Rajkumar S V, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al; Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010 Jan;11(1):29-37.
27. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010 Dec;376(9758):2075-2085.
28. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 2012 Mar;97(3):442-450.
29. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009 Jul;23(7):1337-1341.
30. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009 Aug;114(9):1729-1735.
31. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, et al; IMWG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009 Oct;23(10):1904-1912.
32. Fermand J P, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998 Nov;92(9):3131-3136.
33. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996 Jul;335(2):91-97.
34. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003 May;348(19):1875-1883.
35. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003 Dec;349(26):2495-2502.
36. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009 Jan;101(2):100-106.
37. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998 Dec;16(12):3832-3842.
38. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006 Mar;367(9513):825-831.
39. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007 Oct;370(9594):1209-1218.
40. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, et al; Nordic Myeloma Study Group; Italian Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma Network. Talidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011 Aug;118(5):1239-1247.
41. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropf M, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 Aug;359(9):906-917.
42. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al; GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007 Oct;25(28):4459-4465.
43. Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, et al; Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). Efect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 2011 Dec;90(12):1427-1439.
44. Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 2012 Jul;89(1):16-27.
45. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011 May;12(5):431-440. Published online 18 Apr 2011.
46. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efcacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010 Dec;116(23):4745-4753.
47. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al; International Myeloma Working Group. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012 Mar;119(13):3003-3015.
48. Kagoya Y, Nannya Y, Kurokawa M. Talidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 2012 Aug;36(8):1016-1021. Published online 10 May 2012.
49. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010 Dec;28(34):5101-5109.
50. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 May;366(19):1782-1791.
51. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012 May;366(19):1770-1781.
52. Palumbo A, Hajek R, Delforge M, Kropf M, Petrucci MT, Catalano J, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012 May;366(19):1759-1769.
53. Snowden JA, Ahmedzai SH, Ashcroft J, D'Sa S, Littlewood T, Low E, et al; Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011 Jul;154(1):76-103.
54. Kyle RA, Ye e GC, Somerfeld MR, Flynn PJ, Halabi S, Jagannath S, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007 Jun;25(17):2464-2472.
55. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006 Aug;81(8):1047-1053.
56. Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 2007 Apr;82(4):516-517, author reply 517-518.
57. Palumbo A, Rajkumar S V, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 Feb;22(2):414-423.
58. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011 Mar;29(8):986-993.
59. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010 Nov;28(33):4976-4984. Published online 18 Oct 2010.
60. Rizzo JD, Somerfeld MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008 Jan;26(1):132-149. Published online 22 Oct 2007.
61. Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, et al; International Myeloma Working Group. Te role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008 Aug;22(8):1479-1484. Erratum in: Leukemia. 2008 Aug;22. 8.: 1649. Randall, L. corrected to Randall, RL.
62. Kyle RA, Durie BG, Rajkumar S V, Landgren O, Blade J, Merlini G, et al; International Myeloma Working Group. Monoclonal gammopathy of undetermined signifcance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010 Jun;24(6):1121-1127.
63. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al; Guidelines Working Group of the UK Myeloma Forum; British Committee for Standards in Haematology; British Society for Haematology. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol 2004 Mar;124(6):717-726.
64. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006 Sep;20(9):1467-1473. Published online 20 Jul 2006.
65. Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S, et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012 May;18(5):773-779.
66. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 Nov;357(21):2133-2142.
67. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 Nov;357(21):2123-2132.
68. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, et al; DOXIL-MMY-3001 Study Investigators. Combined pegylated liposomal doxorubicin and bortezomib is highly efective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008 Apr;112(7):1529-1537.
69. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, et al; International Myeloma Working Group. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010 Oct;28(29):4521-4530.
70. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011 Sep;118(11):2970-2975.
71. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carflzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012 Jun;119(24):5661-5670.
72. Rajkumar SV. Treatment of myeloma: cure vs control. Mayo Clin Proc 2008 Oct;83(10):1142-1145.